Literature DB >> 6148957

Enhancement of physiological finger tremor by intravenous isoprenaline infusions in man: evaluation of its role in the assessment of beta-adrenoceptor antagonists.

J M Arnold, D G McDevitt.   

Abstract

Graded intravenous isoprenaline infusions produce dose-related increases in finger tremor. The dose-response curves constructed with intra-arterial or intravenous isoprenaline behave similarly in the presence of both atenolol 50 mg and propranolol 40 mg. In Five subjects, practolol 120 mg, atenolol 50 mg, propranolol 40 mg and sotalol 200 mg reduced exercise heart rate by 20.2 +/- 2.3, 21.4 +/- 1.8, 17.4 +/- 2.5, 23.9 +/- 3.6% respectively: the differences were not significant. The corresponding dose-ratios for reduction of an isoprenaline tachycardia were 2.8, 2.3, 19.1 and 16.9 respectively. At doses which had comparable effects on an exercise tachycardia, the non-selective beta-adrenoceptor antagonists, propranolol 40 mg and sotalol 200 mg, attenuated the finger response to isoprenaline (dose ratios 33.3 and greater than 25.0 respectively) more than the beta 1-selective adrenoceptor antagonists, practolol 120 mg and atenolol 50 mg (dose ratios 1.0 and 2.3 respectively). In two out of five subjects, dose-response curves could not be constructed with sotalol, either at a dose of 200 or 100 mg. The enhancement of physiological finger tremor by intravenous infusions of isoprenaline may be useful in the investigation of beta 2-adrenoceptors and their antagonists in man.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6148957      PMCID: PMC1463531          DOI: 10.1111/j.1365-2125.1984.tb02446.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Evaluation of skeletal muscle tremor due to bronchodilator agents.

Authors:  G Thiringer; N Svedmyr
Journal:  Scand J Respir Dis       Date:  1975-08

2.  Cardiac effects of beta-adrenergic receptor antagonists.

Authors:  B Ablad; B Carlsson; E Carlsson; C Dahlöf; L Ek; E Hultberg
Journal:  Adv Cardiol       Date:  1974

3.  Peripheral beta-adrenergic receptors concerned with tremor.

Authors:  C D Marsden; T H Foley; D A Owen; R G McAllister
Journal:  Clin Sci       Date:  1967-08       Impact factor: 6.124

4.  Propranolol and sotalol as antagonists of isoproterenol-enhanced physiologic tremor.

Authors:  H Pickles; E Perucca; A Fish; A Richens
Journal:  Clin Pharmacol Ther       Date:  1981-09       Impact factor: 6.875

5.  Effect of atenolol, metoprolol, and propranolol on isoproterenol-induced tremor and tachycardia in normal subjects.

Authors:  E Perucca; H Pickles; A Richens
Journal:  Clin Pharmacol Ther       Date:  1981-04       Impact factor: 6.875

6.  Tremor caused by sympathomimetics is mediated by beta2-adrenoreceptors.

Authors:  S Larsson; N Svedmyr
Journal:  Scand J Respir Dis       Date:  1977

7.  Contribution of the vagus to the haemodynamic responses following intravenous boluses of isoprenaline.

Authors:  J M Arnold; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

8.  Heart rate and blood pressure responses to intravenous boluses of isoprenaline in the presence of propranolol, practolol and atropine.

Authors:  J M Arnold; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1983-08       Impact factor: 4.335

9.  An assessment of physiological finger tremor as an indicator of beta-adrenoceptor function.

Authors:  J M Arnold; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1983-08       Impact factor: 4.335

  9 in total
  11 in total

1.  A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol.

Authors:  B J Lipworth; N A Irvine; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  The effects of chronic dosing on the beta 1 and beta 2-adrenoceptor antagonism of betaxolol and atenolol.

Authors:  B J Lipworth; N A Irvine; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Evaluation of the metabolic responses to inhaled salbutamol in the measurement of beta 2-adrenoceptor blockade.

Authors:  B J Lipworth; L C McFarlane; W J Coutie; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Assessment of airways, tremor and chronotropic responses to inhaled salbutamol in the quantification of beta 2-adrenoceptor blockade.

Authors:  B J Lipworth; R A Brown; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

5.  The effects of time and dose on the relative beta 1- and beta 2-adrenoceptor antagonism of betaxolol and atenolol.

Authors:  B J Lipworth; N A Irvine; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

6.  Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man.

Authors:  J M Arnold; P C O'Connor; J G Riddell; D W Harron; R G Shanks; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

7.  Effects of beta-adrenoceptor blockade on heart rate and physiological tremor in diabetics with autonomic neuropathy. A comparative study of epanolol, atenolol and pindolol.

Authors:  W Reid; D J Ewing; J D Harry; H J Smith; J M Neilson; B F Clarke
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

8.  The assessment in man of the beta-adrenoceptor blocking activity and cardioselectivity of H-I 42 BS, a long acting beta-adrenoceptor blocking drug.

Authors:  T H Pringle; A H Deering; M G Scott; D W Harron; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

9.  Characterization of the beta-adrenoreceptors which mediate the isoprenaline-induced changes in finger tremor and cardiovascular function in man.

Authors:  T H Pringle; J G Riddell; R G Shanks
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

10.  The assessment of the beta-adrenoceptor blocking activity and cardioselectivity of Koe 3290 in normal subjects.

Authors:  T H Pringle; A J McNeill; J G Riddell; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.